Navigation Links
Stopping a cancer trial early: is it for the benefit of patients or industry?
Date:4/8/2008

New research has identified a growing trend for trials of new cancer treatments to be stopped prematurely before the therapies risks and benefits have been properly evaluated.

In a study, published online today (Wednesday 9 April) in the cancer journal, Annals of Oncology [1], Italian researchers analysed 25 randomised controlled clinical trials that had been stopped early because they had started to show a benefit to patients and found that the numbers had increased dramatically in recent years. They warn that this could lead to a systematic over-statement of the effects of treatment, and that patients could be harmed by new therapies being rushed prematurely into the clinic.

Out of 14 trials stopped because they started to show benefit to patients and published between 2005-2007, the researchers found that 11 (79%) were used to support an application for marketing authorisation at the European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA).

This suggests a commercial component in stopping trials prematurely. In fact, this strategy (i.e. stopping trials early for benefit) could guarantee quicker access to the market for companies. On the other hand, a quicker clinical drug development may lead to an immature benefit/risk balance of new drugs, Dr Giovanni Apolone, one of the authors, told a news briefing yesterday (Tuesday).

Dr Apolone, head of the Laboratory of Translational and Outcome Research in Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy, continued: When we analysed 25 trials over a ten year period between 1997 and 2007, we found a consistent increase in prematurely stopped trials more than 50% were stopped within the last three years.

We are aware that trials stopped early because they are showing benefit may result in the identification of promising new treatments for patients. However, findings obtained following this strategy should be considered to be preliminary results that require subsequent confirmation. We believe that only untruncated trials can provide the full level of evidence required to safely translate treatments into clinical practice. Without such evidence, unsafe and ineffective drugs could be marketed and prescribed, and patients health could be jeopardised.

He pointed out that it can take several years for the long-term benefits or adverse side-effects of a treatment to become apparent, but the average study duration was 30 months among the 25 trials they analysed (with a range of between 12 and 64 months).

In their paper the authors write: If a trial is evaluating the long-term efficacy of a treatment of conditions such as cancer, short-term benefits, no matter how significant statistically, may not justify early stopping. Data on disease recurrence and progression, drug resistance, metastasis, or adverse events, all factors that weight heavily in the benefit/risk balance, could easily be missed.

An early stop may reduce the likelihood of detecting a difference in overall survival (the only relevant end point in this setting) because of the small sample, the possibility of crossing-over the experimental drugs, and contamination with other treatments.

The authors said they were particularly concerned that, by the time they were stopped, five studies had enrolled less than 40% of the total number of patients planned for final analysis. It is obvious that the risk of overestimating treatment effects increases markedly when the sample is small, they write.

Dr Apolone said: We believe that, in general and unless harm is being shown, cancer trials should be completed so that the correct number of patients over the correct period of time required for a significant final analysis can be recruited. Our study describes a growing phenomenon of trials stopped prematurely, which is now the subject of debate within the international scientific community.

Professor David Kerr, the editor in chief of Annals of Oncology, told the news briefing: We, as scientists, put a great deal of work and effort into designing appropriate clinical trials, and in all but the rarest of cases we should not rush to abandon those designs in the face of early signs of benefit. Moreover, as researchers we make an ethical commitment to patients entering studies to do the research as designed and presented to those patients. Everyone wants new and powerful therapies available quickly in clinic, but we all, patients perhaps most of all, recognise the need for good science and strong ethics.

Professor Stuart Pocock, Professor of Medical Statistics at the London School of Hygiene and Tropical Medicine (UK), who was not involved in the study, told the news briefing: Clinical trials need to stop early for superior benefit whenever theres proof beyond reasonable doubt that the new treatment really is superior. That would be an ethical obligation. However, too many trials are stopped early claiming efficacy without such strong evidence being available.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Stopping a deadly killer
2. Stopping a receptor called nogo boosts the synapses
3. Fugitive cancer cells can be blocked by stopping blood cells that aid them
4. Physicians focus on stopping pain epidemic
5. First 90 Days After Stopping Plavix Most Dangerous
6. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
7. New Sedona Stopping Diabetes Program
8. Common drug for stopping preterm labor may be harmful for babies
9. Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work
10. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
11. Stopping Tysabri May Worsen MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... interactive publication where generations converge and explore the world from different perspectives. By ... Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and ... children with autism spectrum disorder (ASD) to see films in an environment that ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  This report analyzes ... by the following Products: Intermediates, Analytical, ... the report include Pharmaceuticals, and Agrochemicals. The report provides ... , Europe , and Rest ... the period 2015 through 2022. Also, a six-year historic ...
(Date:2/24/2017)... , Feb 24, 2017 Medivir ... proposal for a new Board of Directors that will ... 2016-2017 Nomination Committee comprises representatives of the company,s three ... of 2016 who have accepted a seat on the ... composition of the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... 2017 Visiomed, the French leader in ... is changing the landscape of healthcare with their ... pro-active, custom-made solutions. Recognizing the rising demand of ... healthcare without walls, Visiomed has launched BewellConnect, the ... healthcare professionals that is empowering the lives of ...
Breaking Medicine Technology: